Loading quotes...

Forecast

Buy	6
Hold	4
Sell	0

News Go to news feed

XOMA beats Q4 2025 forecasts by a wide margin and stock rises

XOMA reported Q4 2025 EPS of $0.26 versus an expectation of -$0.11 and revenue of $13.76 million (expectation $11.13 million). The result was driven by higher licensing revenue and milestone payments; annual revenue rose 82.8% and GAAP net income for 2025 was $31.7 million after a loss in 2024. The stock rose 5.19% in premarket trading to $28.40. XOMA expects further growth in 2026 but faces risks from ongoing litigation with Janssen as well as interest costs and reduced free cash. » More on de.investing.com
XOMA Royalty completes acquisition of HilleVax and initiates NASDAQ delisting

XOMA Royalty completed the acquisition of HilleVax for $1.95 per share plus a non-transferable CVR, making HilleVax a wholly owned subsidiary. Approximately 77.48% of outstanding shares were tendered in the offer; as a result, subsidiary XRA 4 Corp. merged with HilleVax and HilleVax’s common stock is to be delisted from the Nasdaq Global Select Market. HilleVax’s management resigned, stock options and RSUs were largely converted into cash claims and CVRs, and XOMA Royalty plans to deregister the shares with the SEC. The CVR provides for potential additional payments from excess liquidity, lease agreement savings, and proceeds from norovirus vaccine programs. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, XOMA CORP.PRF.SH.SER.B 25 Vorzugsaktie has already paid €1.35 in dividends. The last payout was in July.

Financials

In the last quarter, XOMA CORP.PRF.SH.SER.B 25 Vorzugsaktie had revenue of €10.64m and net profit of €3.86m

(EUR)	March 2026	YoY
Revenue	10.64m	-
Gross profit	9.87m	-
Net profit	3.86m	-
EBITDA	7.53m	-

Fundamentals

Metric	Value
Market capitalization	€269.06m
Number of shares	12.06m
52-week high/low	€23.55 - €22.18
Dividend yield	6.15%
Dividends TTM	€1.35
Beta	0.87
P/E ratio	24.35
PEG ratio	-0.17
P/B ratio	4.23
P/S ratio	19.60

Company profile

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.